Duloxetine: Review of its pharmacology, and therapeutic use in depression and other psychiatric disorders

Annals of Clinical Psychiatry

Volumn 19, Issue 2, 2007, Pages 125-132

  Gupta, Sanjay ^a,b   Nihalani, Nikhil ^c   Masand, Prakash ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b Olean General Hospital   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Depression; Duloxetine; Pain symptoms

Indexed keywords

AMFEBUTAMONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; CAFFEINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CODEINE; CYTOKINE; DEXTROMETHORPHAN; DULOXETINE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; PAROXETINE; PHENOTHIAZINE; PROPAFENONE; PSYCHOTROPIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG WITHDRAWAL; FIBROMYALGIA; GLUCOSE BLOOD LEVEL; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFORMED CONSENT; INSOMNIA; LIMB PAIN; LIVER DISEASE; MAJOR DEPRESSION; MENTAL DISEASE; MOTHER; NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; ORGASM DISORDER; PAIN; PANIC; PERIPHERAL EDEMA; PREGNANCY; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STRESS INCONTINENCE; URINARY HESITANCY; URINE RETENTION; VITAL SIGN; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; PAIN; THIOPHENES; TREATMENT OUTCOME;

EID: 34447126350     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230701333319     Document Type: Review

References (49)

1. Adapted from the World Health Organization: World health report, 1999
2. Murray CJL, Lopez AD: Global mortality, disability, and the contribution of risk factors: The Global Burden of Disease Study. Lancet 1997; 349(9063):1463-1472
3. Michaud CM, Murray CJ, Bloom BR.: Burden of disease - implications for research. JAMA 2001; 285:535-539
4. Davidson JRT, Meltzer-Brody SE: The under-recognition and under-treatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999; 60(suppl 7):4-9
5. Fava M: Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry 2002; 63:305-307
6. Von Korff M, Simon G: The relationship between pain and depression. Br J Psychiatry 1996; 30:101-108
7. Hotopf M, Mayou R, Wadsworth M, Wesseley S: Temporal relationship between physical symptoms and psychiatric disorder: Results from a national birth cohort. Br J Psych 1998; 173:255-261
8. Sareen J, Houlahan T, Cox BJ, Asmundson GJ: Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis. 2005 Jul; 1993:450-454
9. Bush KA, Fawcett J, Jacobs DG: Clinical correlates of inpatient suicide. J Clin Psychiatry 2003 Jan; 64:14-19
10. Thase ME, Entsuah R, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psych 2001;178:234-241
11. Wong DT and Bymaster FP: Dual serotonin and noradrenaline uptake inhibitor class of antidepressants-potential for greater efficacy or just hype? Prog Drug Res 2002; 58:169-222
12. Danish University Antidepressant Group: Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18:289-299
13. Tran PV, Bymaster FP, McNamara RK, Potter WZ: Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003; 23:78-86
14. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al.: Compare the affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25:871-880
15. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002; 36:106-132
16. Kihara T, Ikeda M: Duloxetine-induced dose dependent increase of extracellular monoamine in frontal cortex. J Pharmacol Exp Ther 1995; 272:1-183
17. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: Profile of a dual monoamine modulator. CNS Drug Rev 2002; 8:361-376
18. Iyengar S, Bymaster F, Wong D, Ahmad L: Efficacy of the serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain. Annual Meeting of the European College of Neuropsychopharmacology 2002
19. Cymbalta product monograph. Indianapolis, Ind: Eli Lilly and Company; 2004
20. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA: Duloxetine 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315
21. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA: Duloxetine 60 mg daily dosing versus placebo in acute treatment of major depression. J of Psychiatric Res. 2002; 36:383-390
22. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63:225-231
23. Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J: Duloxetine in the treatment of Major Depressive Disorder: A comparison of efficacy in patients with and without melancholic features. BMC Psychiatry. 2005; 5:1
24. Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV: Duloxetine: A new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry. 2003; 5:19-28
25. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I: Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004; 14(6):457-470
26. Norton PA, Zinner NR, Yalcin I, Bump RC: Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002; 187:40-48
27. Guy DR: Duloxetine for the management of stress urinary incontinence. Am J Geriatr Pharmacother 2005; 3:25-28
28. Mallincrokdt CH, Goldstein DJ, Detke MJ, Lu Y, Watkin JG, Tran PV: Duloxetine: A new treatment for the emotional and physical symptoms of depression. Primary Care Companion J Clin Psychiatry 2003; 5:19-28
29. Nemeroff CB, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, Tran PV: Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36:06-132
30. Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinekrodt C: Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005; 25:132-140
31. Masand PS, Gupta S: Long-term of new generation antidepressants: SSRIs, venlafaxine, nefazodone, buproprion, mirtazapine. Ann Clin Psychiatry 2002; 14:175-182
32. Delgado PL, Brannan SK, Mallinekrodt CH, Tran PV, Mc Namara RK, Wang F, Watkin JG, Detke MJ: Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005; 66:686-692
33. Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB: Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003; 64:1237-1244
34. Nirenberg AA, Wright EC: Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry. 1999; 60 (Suppl) 22:7-11
35. Rush A, Trivedi M.:Treating depression to remission. Psychiatr Ann. 1995; 25:704-710
36. Thase ME, Entsuah A, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234-241
37. Thase ME: Full-sustained remission rates among citalopram-treated patients. Annual Meeting of the American Psychiatric Association, May 5-10, 2001, New Orleans, LA.
38. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ: Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003; 18:53-61
39. Wohlreich MM, Mallinckrodt CH, Watkin JG, Hay DP: Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: An open-label study. BMC Geriatr. 2004; 4:11
40. Nelson JC, Wohlreich MM, Mallinckrodt CH, Detke MJ, Watkin JG, Kennedy JS: Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005; 13:227-235
41. Wohlreich MM, Watkin JG: Role of duloxetine in the treatement of depression and associated painful symptoms. Primary Care Companion J Clin Psychiatry 2003; 5:286-287
42. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004; 45:17-28
43. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM: The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates? J Clin Psychiatry. 2004; 65:521-530
44. Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF: A double-blind, randomized multi-center trial comparing duloxetine with placebo in the management of peripheral neuropathic pain. Pain Med. 2005; 5:6346-6356
45. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005; 6:109-118
46. Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, Wernicke JF: J Palliat Med. 2006; 9:29-40
47. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004; 50:2974-2984
48. Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD: Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res. 2005; 39:161-167
49. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA: Duloxetine in the treatment of depression: A double-blind placebo-controlled trial. J Clin Psychopharmacol. 2004; 24:389-399